{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:41:10Z","timestamp":1792644070246,"version":"4.5.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20240813150506008"],"award-info":[{"award-number":["JCYJ20240813150506008"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025B1515020001"],"award-info":[{"award-number":["2025B1515020001"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22307151"],"award-info":[{"award-number":["22307151"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22477150"],"award-info":[{"award-number":["22477150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404699"],"award-info":[{"award-number":["82404699"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119320","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:09:11Z","timestamp":1789225751000},"page":"119320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic applications of metal complexes in lung cancer treatment"],"prefix":"10.1016","volume":"320","author":[{"given":"Jiacheng","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linzhen","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuetong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Ning","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leli","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119320_bib1","first-page":"209","article-title":"Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119320_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Ferlay","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119320_bib3","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer progress and priorities : Lung cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ejmech.2026.119320_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.119320_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev-pathol-012615-044446","article-title":"Mechanisms and consequences of cancer genome instability : lessons from genome sequencing studies","volume":"11","author":"Lee","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejmech.2026.119320_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41389-019-0174-7","article-title":"Epigenetic regulation of lung cancer cell proliferation and migration by the chromatin remodeling protein BRG1","volume":"8","author":"Li","year":"2019","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ejmech.2026.119320_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis : a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119320_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2026.119320_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy : progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119320_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115323","article-title":"Cisplatin in cancer treatment","volume":"206","author":"Romani","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119320_bib11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy : molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119320_bib12","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/cr980421n","article-title":"Structure, recognition, and processing of Cisplatin\u2212DNA adducts","volume":"99","author":"Jamieson","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119320_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119320_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1517\/14656566.6.10.1693","article-title":"Combination therapy versus single agent chemotherapy in non-small cell lung cancer","volume":"6","author":"Cheong","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119320_bib16","first-page":"683","article-title":"Bone-Marrow suppression in elderly patients following empiric radioiodine therapy: real-life data","volume":"29","author":"Hadar Duskin-Bitan","year":"2019","journal-title":"Thyroid Radiol. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119320_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.750507","article-title":"Mechanisms of chemotherapy-induced neurotoxicity","volume":"13","author":"Was","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119320_bib18","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119320_bib19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/cells13050388","article-title":"Cancer drug resistance : targeting proliferation or programmed cell death","volume":"13","author":"Sazonova","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119320_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119320_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"Molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Cancer","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119320_bib25","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"V Sequist","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/resp.12789","article-title":"Scotta. Fisher, immunotherapy for lung cancer","volume":"21","author":"Antonius Steven","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.ejmech.2026.119320_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119320_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14737140.2016.1123626","article-title":"Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer","volume":"16","author":"Dang","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2026.119320_bib29","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3389\/fimmu.2020.01088","article-title":"Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment : a comparison in basic structure , function , and clinical practice","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119320_bib30","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3390\/cancers16122205","article-title":"Promising combinatorial therapeutic strategies against non-small cell lung cancer","volume":"16","author":"Kaur","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119320_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/lungindia.lungindia_321_17","article-title":"Adverse effects observed in lung cancer patients undergoing first - line chemotherapy and effectiveness of supportive care drugs in a resource - limited setting","volume":"36","author":"Muthu","year":"2019","journal-title":"Lung India"},{"key":"10.1016\/j.ejmech.2026.119320_bib32","article-title":"Chemotherapy-induced acute kidney injury : epidemiology, pathophysiology, and therapeutic approaches","volume":"4","author":"Luiza","year":"2024","journal-title":"Front. Nephrol."},{"key":"10.1016\/j.ejmech.2026.119320_bib33","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer","volume":"31","author":"Gainor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib34","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib35","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib36","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/205698a0","article-title":"Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode","volume":"20","author":"Rosenberg","year":"1965","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119320_bib37","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119320_bib38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2165\/00003088-199121040-00002","article-title":"Clinical pharmacokinetics of carboplatin","volume":"21","author":"Van Der Vijgh","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2026.119320_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2165\/00003495-198937020-00005","article-title":"Carboplatin: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer carboplatin","volume":"37","author":"Wagstaff","year":"1989","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119320_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrd1287","article-title":"Oxaliplatin","volume":"3","author":"Graham","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119320_bib41","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3892\/etm.2022.11321","article-title":"Oxaliplatin induces ferroptosis and oxidative stress in HT29 colorectal cancer cells by inhibiting the Nrf2 signaling pathway","volume":"23","author":"Liu","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejmech.2026.119320_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jns.12432","article-title":"Platinum accumulation in oxaliplatin-induced peripheral neuropathy","volume":"26","author":"Wei","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.ejmech.2026.119320_bib43","doi-asserted-by":"crossref","first-page":"9681","DOI":"10.3390\/curroncol29120760","article-title":"The nephrotoxicity of drugs used in causal oncological therapies","volume":"29","author":"Ha\u0142ka","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib44","doi-asserted-by":"crossref","first-page":"22754","DOI":"10.3390\/ijms160922754","article-title":"Interaction of DNA with simple and mixed ligand copper (II) complexes of 1 , 10-Phenanthrolines as studied by DNA-fiber EPR spectroscopy","volume":"16","author":"Chikira","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib45","article-title":"Immunogenic cell death inducing metal complexes for cancer therapy","volume":"62","author":"Lingpu Zhang","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202311437","article-title":"Strategies for the nuclear delivery of metal complexes to cancer cells","volume":"36","author":"Huynh","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejmech.2026.119320_bib47","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/ejic.201900375","article-title":"Heterometallic multinuclear complexes as anti-cancer Agents- an overview of recent developments","author":"Van Niekerk","year":"2019","journal-title":"Eur. J. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202310342","article-title":"Progress and challenges in tumor ferroptosis treatment strategies : a comprehensive review of metal complexes and nanomedicine","volume":"20","author":"Su","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.ejmech.2026.119320_bib49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s10020-024-00899-4","article-title":"Mitochondria : a new intervention target for tumor invasion and metastasis","volume":"30","author":"Zhou","year":"2024","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119320_bib50","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2174\/0929867325666180307112029","article-title":"Mitochondria-targeting anticancer metal complexes","volume":"26","author":"Erxleben","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400120","article-title":"Mitochondria-targeting metallodrugs for cancer therapy : perspectives from cell death modes","volume":"19","author":"Li","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119320_bib52","article-title":"Mitochondria-targeted metallo-drugs against cancer : a current mechanistic perspective, results","volume":"6","author":"Pal","year":"2023","journal-title":"Chem"},{"key":"10.1016\/j.ejmech.2026.119320_bib53","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.3390\/molecules24152739","article-title":"Iridium (III) complexes targeting apoptotic cell death in cancer cells","volume":"24","author":"Ma","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119320_bib54","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.2147\/DDDT.S275007","article-title":"Ruthenium complexes as anticancer agents : a brief history and perspectives","author":"Lee","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2026.119320_bib55","doi-asserted-by":"crossref","first-page":"447","DOI":"10.31557\/APJCP.2021.22.2.447","article-title":"Evaluation of the synthesized novel iridium (III) complexes against HeLa cell lines through In-Silico , In-Vitro and DNA nicking","volume":"22","author":"Priyadarshini","year":"2021","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.ejmech.2026.119320_bib56","article-title":"Current status of iridium-based complexes against lung cancer","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119320_bib57","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/ijms24020952","article-title":"Ruthenium complex HB324 induces apoptosis via mitochondrial pathway with an upregulation of harakiri and overcomes cisplatin resistance in neuroblastoma cells in vitro","volume":"24","author":"Wilke","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2022.112054","article-title":"Anticancer effect evaluation of iridium (III) complexes targeting mitochondria and endoplasmic reticulum","volume":"238","author":"Wang","year":"2023","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119320_bib59","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1039\/D2SC06675K","article-title":"A mitochondria-localized iridium(III) photosensitizer for two-photon photodynamic immunotherapy against melanoma","volume":"14","author":"Wang","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115046","article-title":"Synthesis , biological evaluation of novel iridium (III) complexes targeting mitochondria toward melanoma B16 cells","volume":"247","author":"Yuan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib61","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1021\/acs.jmedchem.3c02018","article-title":"Antitumor activity and mechanistic insights of a Mitochondria- targeting Cu(I) complex","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2023.112295","article-title":"Ruthenium (II) complexes as mitochondrial inhibitors of topoisomerase induced A549 cell apoptosis","volume":"246","author":"Tang","year":"2023","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119320_bib63","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1039\/c3mt20270d","article-title":"The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium(II) asymmetric complexes","volume":"5","author":"Qian","year":"2013","journal-title":"Metallomics"},{"key":"10.1016\/j.ejmech.2026.119320_bib64","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jphotobiol.2014.07.011","article-title":"Ruthenium (II) complexes : DNA-binding, cytotoxicity, apoptosis, cellular localization, cell cycle arrest, reactive oxygen species, mitochondrial membrane potential and Western blot analysis","volume":"140","author":"Li","year":"2014","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"10.1016\/j.ejmech.2026.119320_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217582","article-title":"Discovery and antitumor evaluation of a mitochondria-targeting ruthenium complex for effective cancer therapy","volume":"616","author":"Liu","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119320_bib66","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1038\/s41467-025-58528-5","article-title":"Peripheral positioning of lysosomes supports melanoma aggressiveness","volume":"16","author":"Jerabkova-roda","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119320_bib67","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.3390\/molecules26154389","article-title":"Ruthenium complexes as promising candidates against lung cancer","volume":"26","author":"Sun","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119320_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2022.111729","article-title":"Lysosome-targeted ruthenium (II) complexes induce both apoptosis and autophagy in HeLa cells","volume":"229","author":"Pan","year":"2022","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119320_bib69","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1021\/acs.jmedchem.3c01978","article-title":"Novel 2-(5-Arylthiophen-2-yl)-benzoazole cyclometalated Iridium(III) dppz complexes exhibit selective phototoxicity in cancer cells by lysosomal damage and oncosis","volume":"67","author":"Jana Kasparkova","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib70","doi-asserted-by":"crossref","first-page":"19572","DOI":"10.1021\/acsami.0c22551","article-title":"Red-light-responsive Ru complex photosensitizer for lysosome localization photodynamic therapy","volume":"13","author":"He","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejmech.2026.119320_bib71","doi-asserted-by":"crossref","first-page":"8991","DOI":"10.1021\/jacs.3c13224","article-title":"Augmenting cancer therapy with a supramolecular immunogenic cell death inducer: a lysosome-targeted NIR-Light-Activated Ruthenium(II) metallacycle","volume":"146","author":"Tu","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119320_bib72","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.biomaterials.2017.03.017","article-title":"Ruthenium complexes with phenylterpyridine derivatives target cell membrane and trigger death receptors-mediated apoptosis in cancer cells","volume":"129","author":"Deng","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2026.119320_bib73","doi-asserted-by":"crossref","first-page":"10137","DOI":"10.1021\/ic401573d","article-title":"Dicopper(II) and Dizinc(II) complexes with nonsymmetric dinucleating ligands based on Indolo[3,2 - c ]quinolines: synthesis, structure, cytotoxicity, and intracellular distribution","volume":"52","author":"Primik","year":"2013","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202312170","article-title":"A golgi-targeted platinum complex plays a dual role in autophagy regulation for highly efficient cancer therapy","volume":"62","author":"Liang","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib75","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1586\/14737140.2016.1170596","article-title":"Platinum-based chemotherapy in advanced non-small-cell lung cancer : optimal number of treatment cycles","volume":"16","author":"Antonio Rossi","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2026.119320_bib76","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected Non\u2013small-cell lung cancer","volume":"350","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119320_bib77","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1054\/bjoc.2001.1784","article-title":"Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer : a multicentre phase II study","volume":"84","author":"Douillard","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119320_bib78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity : a review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejmech.2026.119320_bib79","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity : mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2026.119320_bib80","doi-asserted-by":"crossref","first-page":"58","DOI":"10.15171\/jept.2016.09","article-title":"Hypersensitivity and cross-reactivity to cisplatin and carboplatin","volume":"2","author":"Faridaalaee","year":"2016","journal-title":"J. Emerg. Pract. Trauma"},{"key":"10.1016\/j.ejmech.2026.119320_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009256.pub3","article-title":"Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer","author":"Vasconcellos","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2026.119320_bib82","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/cam4.1569","article-title":"Phase II study of carboplatin , pemetrexed , and bevacizumab in advanced nonsquamous non \u2013 small- - cell lung cancer","volume":"7","author":"Schneider","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejmech.2026.119320_bib83","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for Colon cancer","volume":"350","author":"Topham","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119320_bib84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3816\/CLC.2010.n.003","article-title":"Oxaliplatin in first-line therapy for advanced non \u2013 small-cell lung cancer","volume":"11","author":"Raez","year":"2010","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ejmech.2026.119320_bib85","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2008.03.028","article-title":"Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer","volume":"62","author":"Fr\u00fch","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2026.119320_bib86","article-title":"Oxaliplatin-based doublets versus cisplatin or carboplatin-based doublets in the first-line treatment of advanced nonsmall cell lung cancer","volume":"94","author":"Cell","year":"2015","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ejmech.2026.119320_bib87","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.3390\/ijms26167958","article-title":"Research progress of platinum-based complexes in lung cancer treatment : mechanisms , applications , and challenges","volume":"26","author":"Liang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib88","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jconrel.2023.08.035","article-title":"Emerging platinum (IV) prodrug nanotherapeutics : a new epoch for platinum-based cancer therapy","volume":"361","author":"Zheng","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2026.119320_bib89","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1039\/c5mt00312a","article-title":"Behavior of platinum(IV) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation","volume":"8","author":"Schreiber-brynzak","year":"2016","journal-title":"Metallomics"},{"key":"10.1016\/j.ejmech.2026.119320_bib90","first-page":"3085","article-title":"Advances in technical strategies for monitoring the reduction of platinum(IV) complexes","volume":"11","author":"Chen","year":"2024","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ica.2023.121388","article-title":"An overview of recent advancements in anticancer Pt (IV) prodrugs : new smart drug combinations, activation and delivery strategies","volume":"548","author":"Marotta","year":"2023","journal-title":"Inorg. Chim. Acta."},{"key":"10.1016\/j.ejmech.2026.119320_bib92","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4236\/ijmpcero.2018.72020","article-title":"Current status for oral platinum (IV) anticancer drug development","volume":"7","author":"Mi","year":"2018","journal-title":"Int. J. Med. Phys. Clin. Eng. Radiat. Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib93","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/13543780903362437","article-title":"Satraplatin : leading the new generation of oral platinum agents satraplatin : leading the new generation of oral platinum agents","volume":"18","author":"Bhargava","year":"2009","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2026.119320_bib94","article-title":"The anti-neoplastic potency of epoxy-substituted polyaromatic platinum (II) and platinum (IV) complexes against A549 lung cancer cells","volume":"294","author":"Al","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib95","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119320_bib96","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tips.2005.01.002","article-title":"Mechanisms of platinum drug resistance","volume":"26","author":"Ohmichi","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.137366","article-title":"Platinum-based drugs in cancer treatment : expanding horizons and overcoming resistance","volume":"1301","author":"Shahlaei","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2026.119320_bib98","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3390\/cancers13092073","article-title":"Platinum complexes in colorectal cancer and other solid tumors","volume":"13","author":"K\u00f6berle","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119320_bib99","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/molecules29040746","article-title":"Current status of novel multifunctional targeted Pt (IV) compounds and their reductive release properties","volume":"29","author":"Xu","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119320_bib100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fphar.2020.00343","article-title":"The drug-resistance mechanisms of five platinum-based antitumor agents","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119320_bib101","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs : targeted Pt (II) agents , nanoparticle delivery, and Pt (IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119320_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202505930","article-title":"Evoking simultaneous ferroptosis and apoptosis by a dual-locked platinum (IV) prodrug for synergistic chemo-immunotherapy","volume":"64","author":"Meng","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib103","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/1878-0261.13555","article-title":"Identification of protein biomarkers for prediction of response to platinum-based treatment regimens in patients with non-small cell lung cancer","volume":"18","author":"Radonic","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1242488","article-title":"Metallodrugs in the battle against non-small cell lung cancer : unlocking the potential for improved therapeutic outcomes","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119320_bib105","article-title":"Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119320_bib106","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1023\/A:1026243000320","article-title":"Biological role of adduct formation of the ruthenium (III) complex NAMI-A with serum albumin and serum transferrin","volume":"21","author":"Bergamo","year":"2003","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2026.119320_bib107","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2174\/1568026043387421","article-title":"Ruthenium antimetastatic agents","volume":"4","author":"Alessio","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib108","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/cbdv.200890195","article-title":"KP1019 , A new redox-active anticancer agent \u2013 preclinical development and results of a clinical phase I study in tumor patients","volume":"5","author":"Hartinger","year":"2008","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2026.119320_bib109","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10637-016-0337-8","article-title":"Molecular mode of action of NKP-1339 \u2013 a clinically investigated ruthenium-based drug \u2013 involves ER- and ROS-related effects in colon carcinoma cell lines","volume":"34","author":"Flocke","year":"2016","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2026.119320_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24101995","article-title":"NAMI-A and KP1019\/1339, two iconic ruthenium anticancer drug candidates Face-to-Face: a case story in medicinal inorganic chemistry","volume":"24","author":"Alessio","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119320_bib111","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.bcp.2005.10.053","article-title":"Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium (II) based organo-metallic compounds","volume":"71","author":"Guichard","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119320_bib112","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1039\/D1MD00220A","article-title":"Ruthenium(II)\u2013arene complexes as anti-metastatic agents, and related techniques","volume":"13","author":"Sonkar","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113840","article-title":"Mitochondria-targeted and ROS-sensitive main-chain ruthenium polymer overcomes cancer drug resistance","volume":"383","author":"Li","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2026.119320_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202218000","article-title":"Gold complexes in anticancer therapy : from new design principles to particle-based delivery systems angewandte","volume":"62","author":"Moreno-Alc\u00e1ntar","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13046-024-03012-z","article-title":"Auranofin repurposing for lung and pancreatic cancer : low CA12 expression as a marker of sensitivity in patient - derived organoids , with potentiated efficacy by AKT inhibition","volume":"43","author":"Deben","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119320_bib116","doi-asserted-by":"crossref","first-page":"783","DOI":"10.31635\/ccschem.023.202303190","article-title":"Multitarget thiol-activated tetrapyridyl gold (III) complexes for hypoxic cancer therapy","volume":"6","author":"Zhou","year":"2024","journal-title":"CCS Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202422763","article-title":"Stability and mitochondrial localization of a highly cytotoxic Organogold (III) complex with diphosphine ancillary ligand in lung cancer cells","volume":"64","author":"Blommaert","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib118","doi-asserted-by":"crossref","first-page":"15291","DOI":"10.1039\/D4SC04585H","article-title":"Comparative study of the antiproliferative activity of heterometallic carbene gold(I)\u2013platinum(II) and gold(I)\u2013palladium(II) complexes in cancer cell lines","volume":"15","author":"Dietl","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib119","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/ph17091133","article-title":"Anticancer activity of imidazolyl gold (I\/III) compounds in non-small cell lung cancer cell lines","volume":"17","author":"Galassi","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119320_bib120","doi-asserted-by":"crossref","first-page":"15719","DOI":"10.1021\/jacs.5c03186","article-title":"Subcellular photocatalysis enables tumor-targeted inhibition of thioredoxin reductase I by Organogold(I) complexes","volume":"147","author":"Liu","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119320_bib121","doi-asserted-by":"crossref","first-page":"15176","DOI":"10.1039\/D4DT01677G","article-title":"Anticancer activity and mechanism studies of photoactivated iridium(III) complexes toward lung cancer A549 cells","volume":"53","author":"Zhou","year":"2024","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2026.119320_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1562228","article-title":"Radiosensitization effect of iridium (III) complex on lung cancer cells via mitochondria apoptosis pathway","volume":"16","author":"Pang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119320_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2021.111550","article-title":"Iridium (III)-BBIP complexes induce apoptosis via PI3K\/AKT\/mTOR pathway and inhibit A549 lung tumor growth in vivo","volume":"223","author":"Zhou","year":"2021","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119320_bib124","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/molecules29010256","article-title":"Recent advances in organometallic NIR iridium (III) complexes for detection and therapy","volume":"29","author":"Jing","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119320_bib125","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1039\/D0SC06885C","article-title":"Phosphorescent metal complexes as theranostic anticancer agents : combining imaging and therapy in a single molecule","volume":"12","author":"Tan","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib126","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2316615121","article-title":"Iridium(III) carbene complexes as potent girdin inhibitors against metastatic cancers","volume":"121","author":"Ruan","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103536","article-title":"A rhodamine-coordinated iridium complex to overcome cisplatin-resistant cancer via regulating mitochondrial function triggered apoptosis and ferroptosis","volume":"81","author":"Li","year":"2025","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejmech.2026.119320_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2021.214088","article-title":"Zinc coordination complexes as anticancer agents","volume":"445","author":"Pellei","year":"2021","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119320_bib129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijc.34679","article-title":"Roles of zinc in cancers : from altered metabolism to therapeutic applications","volume":"154","author":"Leli\u00e8vre","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119320_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107422","article-title":"In vitro and in vivo antiproliferative activity on lung cancer of two acylhydrazone based zinc (II) complexes","volume":"147","author":"Chang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib131","first-page":"65","article-title":"Preparation and characterisation of zinc diethyldithiocarbamate \u2013 cyclodextrin inclusion complexes for potential lung cancer treatment","volume":"16","author":"Arafat","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119320_bib132","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202112236","article-title":"Clinical development of metal complexes as photosensitizers for photodynamic therapy of cancer","volume":"61","author":"Karges","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2021.111526","article-title":"Oxoplatin-B, a cisplatin-based platinum (IV) complex with photoactive BODIPY for mitochondria specific \u201cchemo-PDT\u201d activity","volume":"223","author":"Bera","year":"2021","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119320_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202400476","article-title":"A photodynamic and photochemotherapeutic platinum-iridium charge-transfer conjugate for anticancer therapy angewandte","volume":"63","author":"Shi","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/ph13070137","article-title":"TLD1433-Mediated photodynamic therapy with an optical surface applicator in the treatment of lung cancer cells in vitro","volume":"13","author":"Chamberlain","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119320_bib136","doi-asserted-by":"crossref","first-page":"17653","DOI":"10.1021\/acs.jmedchem.5c01371","article-title":"Nonemissive ruthenium complexes for near Infrared-II photodynamic, photothermal, sonodynamic, and sonothermal therapy against drug-resistant cancer","volume":"68","author":"Song","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib137","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202212689","article-title":"Organogold(III) complexes display conditional photoactivities: evolving from photodynamic into photoactivated chemotherapy in response to O2 consumption for robust cancer therapy","volume":"61","author":"Luo","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib138","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1039\/D1SC05478C","article-title":"Recent advances in noble metal complex based photodynamic therapy","volume":"13","author":"Wu","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib139","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/molecules28020691","article-title":"N -Heterocyclic carbene-iridium complexes as photosensitizers for in vitro photodynamic therapy to trigger non-apoptotic cell death in cancer cells","volume":"28","author":"Wang","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119320_bib140","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1039\/D0DT00180E","article-title":"Cyclometalated iridium(III) complexes for mitochondria-targeted combined chemo-photodynamic therapy","volume":"49","author":"Qin","year":"2020","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2026.119320_bib141","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/pharmaceutics13091382","article-title":"Dual emissive Ir (III) complexes for photodynamic therapy and bioimaging","volume":"13","author":"Redrado","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119320_bib142","article-title":"Inducing immunogenic cancer cell death through oxygen-economized photodynamic therapy with nitric oxide-releasing photosensitizers","volume":"63","author":"Xu","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib143","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1016\/j.bmc.2019.03.051","article-title":"Synthesis, characterization, and photodynamic therapy activity of 5,10,15, 20-Tetrakis(carboxyl)porphyrin","volume":"27","author":"Zhang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib144","first-page":"227","article-title":"Nanostructured delivery system for zinc phthalocyanine : preparation , characterization , and phototoxicity study against human lung adenocarcinoma A549 cells","volume":"6","author":"Quaresma","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejmech.2026.119320_bib145","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1186\/s12885-025-14386-4","article-title":"Photodynamic therapeutic activity of novel porphyrins against lung squamous cell carcinoma","volume":"25","author":"Meng","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2026.119320_bib146","article-title":"Strategic design of conquering hypoxia in tumor for advanced photodynamic therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejmech.2026.119320_bib147","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41392-025-02140-y","article-title":"Phototherapy in cancer treatment: strategies and challenges","volume":"10","author":"Cai","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119320_bib148","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1039\/D2CS00407K","article-title":"Medicinal inorganic chemistry - challenges, opportunities and guidelines to develop the next generation of radioactive, photoactivated and active site inhibiting metal-based medicines","volume":"51","author":"Lengacher","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119320_bib149","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119320_bib150","article-title":"Article immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer ll immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plu","volume":"5","author":"Galsky","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejmech.2026.119320_bib151","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12967-020-02523-5","article-title":"A phase 2 study of combined chemo - immunotherapy with cisplatin - pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma","volume":"18","author":"Yeku","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119320_bib152","article-title":"A ruthenium (II) complex inhibits BRD4 for synergistic Seno- and chemo-immunotherapy in cisplatin-resistant tumor cells","volume":"64","author":"Yang","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib154","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1002\/anie.202013987","article-title":"An ER-Targeting iridium (III) complex that induces immunogenic cell death in non-small-cell lung cancer","volume":"60","author":"Wang","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib153","doi-asserted-by":"crossref","first-page":"10779","DOI":"10.1039\/D2SC03756D","article-title":"BQ-AurIPr: a redox-active anticancer Au(I) complex that induces immunogenic cell death","volume":"13","author":"Mule","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib155","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119320_bib156","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119320_bib157","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10637-014-0179-1","article-title":"Phase I\/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy","volume":"33","author":"Leijen","year":"2015","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2026.119320_bib158","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1039\/C3SC53243G","article-title":"NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application","volume":"5","author":"Trondl","year":"2014","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib159","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1016\/j.ejca.2013.05.018","article-title":"The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo","volume":"49","author":"Heffeter","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119320_bib160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/biomedicines12010183","article-title":"Overcoming chemotherapy resistance in metastatic cancer : a comprehensive review","volume":"12","author":"Behnam","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.119320_bib161","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.3390\/ijms19103183","article-title":"Evaluation for synergistic effects by combinations of photodynamic therapy (PDT) with temoporfin (mTHPC) and Pt (II) complexes carboplatin , cisplatin or oxaliplatin in a set of five human cancer cell lines","volume":"19","author":"Lange","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119320_bib162","first-page":"1071","article-title":"Photodynamic therapy combined with PD-1 inhibitor for bronchial tumors: one case report and literature review","volume":"2","author":"Jingyu","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.ejmech.2026.119320_bib163","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1021\/acs.jmedchem.2c00698","article-title":"Developing a copper (II) agent based on His-146 and His-242 residues of human serum albumin nanoparticles : integration to overcome cisplatin resistance and inhibit the metastasis of nonsmall cell lung cancer","volume":"65","author":"Jiang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib164","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202411846","article-title":"Anticancer tetranuclear Cu(I) complex catalyzes a click reaction to synthesize a chemotherapeutic agent in situ to achieve targeted dual-agent combination therapy for cancer","volume":"63","author":"Man","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119320_bib165","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1021\/acs.jmedchem.1c01790","article-title":"Developing a novel indium (III) agent based on human serum albumin nanoparticles : integrating bioimaging and therapy","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib166","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1021\/acs.jmedchem.2c01904","article-title":"Developing a gadolinium (III) compound based on apoferritin for targeted magnetic resonance imaging and dual-modal therapy of cancer","volume":"66","author":"Man","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib167","doi-asserted-by":"crossref","first-page":"17243","DOI":"10.1021\/acs.jmedchem.4c01133","article-title":"Developing a Rhodium(III) complex to reprogram the tumor immune and metabolic microenvironments: overcoming multidrug resistance and metastasis in non-small cell lung cancer","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib168","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1021\/acs.jmedchem.3c00001","article-title":"Developing an anticancer platinum (II) compound based on the uniqueness of human serum albumin","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib169","doi-asserted-by":"crossref","first-page":"8599","DOI":"10.1021\/acs.jmedchem.6c00360","article-title":"Developing a multitargeted anticancer Bi-Copper(II)-Centered thiocarbohydrazone agent based on Lys-199 and His-242 residues in the IIA subdomain of human serum albumin","volume":"69","author":"Li","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib170","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1021\/acs.jmedchem.5c01882","article-title":"Developing a Vanadium(IV) complex for targeted inhibition of growth and metastasis of tumors by multiacting on cancer cells and dual activating immune system","volume":"69","author":"Gao","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119320_bib171","doi-asserted-by":"crossref","first-page":"13113","DOI":"10.1021\/acs.jmedchem.5c01235","article-title":"Development of a high-efficacy and low-toxicity Cobalt(II) agent for targeting inhibition of tumor growth through mitochondrial damage-mediated chemotherapy and immunotherapy","volume":"68","author":"Zhu","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:26:10Z","timestamp":1792643170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":171,"alternative-id":["S0223523426007658"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119320","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic applications of metal complexes in lung cancer treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119320"}}